It is estimated that more than 2.4 million women in the United States have vulvodynia.
Many of these women use contraception containing both estrogen and progestin. Hormonal
contraception has been shown to affect serum level of sex hormone-binding globulin
(SHBG), a protein binds free testosterone. The goal of this study is to explore the
differences and relationships among SHBG levels, serum testosterone and sexual pain
in vulvodynia patients using various hormonal contraception regimens.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Publication history
Accepted:
April 26,
2010
Received:
April 26,
2010
Identification
Copyright
© 2010 Published by Elsevier Inc.
